GLP-1s and Breast Cancer: What We Know and What Still Needs Study

GLP-1 medicines are being studied in relation to breast cancer, but promising early findings do not establish that they prevent breast cancer or stop it returning. For someone managing weight changes during or after treatment, the useful question is how metabolic care fits safely into the cancer care they already need.

Dr. Anne Peled brings two perspectives to her interview with Ana Reisdorf: she is a breast cancer and reconstruction surgeon and a breast cancer survivor. She describes being diagnosed at 37 and again at 44. That experience informs her emphasis on asking questions, taking new symptoms seriously and building an individualized plan.

Why researchers are interested in GLP-1 medicines

Peled discusses the connections among body fat, hormones and breast cancer. There is an established reason to study those relationships: the National Cancer Institute identifies excess body fat as associated with several cancers, including postmenopausal breast cancer. It also describes possible biological pathways involving estrogen, insulin and inflammation.

That background creates a research question. It does not answer whether a particular medicine changes a particular person’s cancer risk. A plausible mechanism and a treatment that produces weight loss are not enough to establish cancer prevention.

Peled herself draws a boundary when the conversation turns to taking a GLP-1 at a normal BMI solely to prevent cancer. She says the evidence does not support that use. Her interest in future research should not be mistaken for a recommendation to start treatment for that purpose now.

A lower cancer rate in a study is not yet proof of prevention

In June 2026, Penn Medicine reported its retrospective study of breast cancer incidence among women who had breast imaging. Women with documented GLP-1 prescriptions had lower odds of a new breast cancer diagnosis than comparison participants. The investigators described the findings as observational and said prospective research is needed.

Looking backward through medical records can reveal a pattern, but it cannot fully rule out other differences between people who received a medicine and those who did not. The study also did not account for the specific GLP-1 medicine or duration of use. Its participants and methods matter when interpreting the result.

There is a separate question about recurrence after an existing cancer. A study of new diagnoses does not settle that question. NCI notes that evidence on whether weight loss reduces breast cancer recurrence or death remains limited. It would be misleading to turn these developing findings into a promise of protection.

Weight changes during treatment deserve a real conversation

Peled describes a difficult situation she sees in practice: a treatment that is important for cancer care may coincide with weight changes that are upsetting to the patient. Hormonal treatment, menopause-related changes, chemotherapy and the disruption of normal routines can all enter that conversation. Reducing it to willpower misses the problem the person is trying to manage.

Her approach is to consider metabolic concerns alongside cancer care, rather than forcing a choice between them. The appropriate response depends on the treatment plan, nutritional status, symptoms and the person’s other health conditions. A GLP-1 discussion belongs with the clinicians who understand those details.

This is also why a successful weight intervention cannot be judged only by pounds lost. Someone preparing for surgery or recovering from treatment needs a plan that supports nourishment and recovery. Appetite suppression that makes eating difficult deserves attention even if the scale is moving.

Coordinate nutrition and procedure planning

When Reisdorf asks about getting enough nutrition before surgery, Peled emphasizes protein intake and a thoughtful, coordinated approach. The practical insight is that the prescriber, cancer team and surgical team need to know what is happening. A distant prescribing service cannot replace that coordination.

Tell the team about all medicines you take and any trouble eating, vomiting or other digestive symptoms. Ask for instructions specific to your procedure and anesthesia plan. The interview describes Peled’s practice at the time; it should not be used as a universal instruction about when to start or hold a GLP-1 before surgery.

For day-to-day food decisions, our article with nutritionist Rob Hobson explains how smaller, practical meal components can help when appetite is low. During cancer treatment or surgical recovery, adapt those ideas with a dietitian who knows your needs.

Keep screening and symptom evaluation in the picture

Peled recalls finding a lump and initially encountering the assumption that she was too young for breast cancer. Her experience supports a concrete action: a new breast concern deserves a clinical conversation. It should not be dismissed because you are younger than a routine screening age or taking a medicine that is being studied for possible benefits.

Routine screening and evaluation of a symptom are different. The USPSTF recommends mammograms every two years from 40 to 74 for its average-risk screening population. That recommendation does not apply to people with a previous breast cancer or certain high-risk conditions. Peled discusses more individualized schedules in her practice; your own history determines which plan fits.

Before the next appointment, write down the question you most need answered: a new symptom, a screening plan, a treatment-related weight change or difficulty nourishing yourself. Peled encourages patients to seek another opinion when they need clarity. The aim is to make a well-informed decision with the relevant team, rather than let an encouraging research headline make it for you.